Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
Luigi Fattore, Ciro Francesco Ruggiero, Maria Elena Pisanu et al. · Cell Death and Differentiation · 2018
Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical recurrences and untreatable disease. Hence, there is strong need of developing new combination therapies and non-invasive diagnostics for the early identification of drug-resistant patients. We report here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis. Significant alterations of miRNA expression levels are detectable in tumor biopsies and plasma from patients after disease recurrence. Targeting these alterations blunts the development of drug resistance.
Cited by 69 works. doi:10.1038/s41418-018-0205-5 Open-access PDF
Authors
- Luigi Fattore
- Ciro Francesco Ruggiero
- Maria Elena Pisanu
- Domenico Liguoro
- Andrea Cerri
- Susan Costantini
- Francesca Capone
- Mario Acunzo
- Giulia Romano
- Giovanni Nigita
- Domenico Mallardo
- Concetta Ragone
- Maria Vincenza Carriero
- Alfredo Budillon
- Gerardo Botti
- Paolo A. Ascierto
- Rita Mancini
- Gennaro Ciliberto
References
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- The role of BRAF V600 mutation in melanoma
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- Clinical relevance of circulating cell-free microRNAs in cancer
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
- Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction